Fiche publication
Date publication
novembre 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GAIDDON Christian
,
Dr MELLITZER Georg
Tous les auteurs :
Badie A, Gaiddon C, Mellitzer G
Lien Pubmed
Résumé
Gastric cancer (GC) is one of the most aggressive cancers. Therapeutic treatments are based on surgery combined with chemotherapy using a combination of platinum-based agents. However, at metastatic stages of the disease, survival is extremely low due to late diagnosis and resistance mechanisms to chemotherapies. The development of new classifications has not yet identified new prognostic markers for clinical use. The studies of epigenetic processes highlighted the implication of histone acetylation status, regulated by histone acetyltransferases (HATs) and by histone deacetylases (HDACs), in cancer development. In this way, inhibitors of HDACs (HDACis) have been developed and some of them have already been clinically approved to treat T-cell lymphoma and multiple myeloma. In this review, we summarize the regulations and functions of eighteen HDACs in GC, describing their known targets, involved cellular processes, associated clinicopathological features, and impact on survival of patients. Additionally, we resume the in vitro, pre-clinical, and clinical trials of four HDACis approved by Food and Drug Administration (FDA) in cancers in the context of GC.
Mots clés
biomarker, gastric cancer, histone deacetylase, histone deacetylase inhibitor
Référence
Cancers (Basel). 2022 11 7;14(21):
